Detalhe da pesquisa
1.
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort.
J Neurol Neurosurg Psychiatry
; 95(1): 52-60, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879898
2.
3D-Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient-Derived Glioma Cells.
Small
; 18(49): e2204485, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36207287
3.
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Acta Neuropathol
; 141(6): 945-957, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740099
4.
Tumor-specific mutations in low-frequency genes affect their functional properties.
J Neurooncol
; 122(3): 461-70, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25694352
5.
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
Sci Immunol
; 7(75): eabq4450, 2022 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737747
6.
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Neuro Oncol
; 24(3): 429-441, 2022 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34608482
7.
Human branching cholangiocyte organoids recapitulate functional bile duct formation.
Cell Stem Cell
; 29(5): 776-794.e13, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35523140
8.
Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.
EBioMedicine
; 56: 102796, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32512509
9.
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
Neurooncol Adv
; 2(1): vdz051, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32642719
10.
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
PLoS One
; 13(6): e0199737, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29953513
11.
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Cancer Res
; 76(3): 525-34, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26762204